{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:06:23Z","timestamp":1791241583495,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Most antiemetic studies have been conducted in patients with solid tumors receiving single-dose chemotherapy. A research gap leaves healthcare providers without clear guidance on effective antiemetic regimens and schedules for patients with hematologic malignancies undergoing high-dose multiday chemotherapy. This literature search identified antiemetic studies and assessed efficacy outcomes in the hematology setting, and specifically in patients receiving high-dose chemotherapy prior to hematopoietic stem cell transplantation (HSCT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A literature review of both PubMed and Embase was performed for published studies evaluating antiemetic regimens including an NK1 receptor antagonist (RA) and\/or a 5HT-3RA with\/without dexamethasone in the hematology setting. Key features of all studies are reviewed, and antiemetic efficacy is summarized specifically for studies in which patients received high-dose chemotherapy prior to HSCT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twenty-two of an initial 926 identified publications met the predefined inclusion criteria. The studies were heterogenous, with varying characteristics pertaining to randomization, control groups, size, cancer types, chemotherapies, antiemetics, and assessments, making cross-study comparisons and conclusions difficult. The range of response rates was wide with numerous studies showing complete response, no emesis or no nausea rates of less than 50%. Response rates were highest when an NK1 RA regimen was administered; however, an NK1 RA was underutilized and only administered in two-thirds of the studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The results reflect a significant clinical problem in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with hematologic malignancies. The scarcity and heterogeneity of studies highlight challenges inherent in this area. This underscores a pressing need for rigorous randomized trials in hematology and HSCT assessing treatment-related CINV and effectiveness of antiemetic regimens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09638-9","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T04:06:36Z","timestamp":1750737996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring antiemetic strategies in hematologic malignancies: a comprehensive literature review and evaluation of antiemetic efficacy in patients receiving high-dose chemotherapy prior to hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-5938","authenticated-orcid":false,"given":"Karin","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Vanden","family":"Burgt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"21","key":"9638_CR1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3238\/arztebl.m2022.0093","volume":"119","author":"F Jahn","year":"2022","unstructured":"Jahn F, W\u00f6rmann B, Brandt J, Freidank A, Feyer P, Jordan K (2022) The prevention and treatment of nausea and vomiting during tumor therapy. Dtsch Arztebl Int 119(21):382\u2013392. https:\/\/doi.org\/10.3238\/arztebl.m2022.0093","journal-title":"Dtsch Arztebl Int"},{"issue":"14","key":"9638_CR2","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"key":"9638_CR3","unstructured":"Yu P. (2014) ASCO 50th anniversary poll names the top 5 advances from the past 50 years. The ASCO post. https:\/\/ascopost.com\/issues\/october-15-2014\/. Accessed 11 Jun 1999"},{"issue":"1","key":"9638_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/jco.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103\u2013109. https:\/\/doi.org\/10.1200\/jco.1997.15.1.103","journal-title":"J Clin Oncol"},{"issue":"1","key":"9638_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00520-023-08220-5","volume":"32","author":"K Jordan","year":"2023","unstructured":"Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Ruhlmann CH et al (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC\/ESMO consensus recommendation. Support Care Cancer 32(1):53. https:\/\/doi.org\/10.1007\/s00520-023-08220-5","journal-title":"Support Care Cancer"},{"issue":"9","key":"9638_CR6","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/jco.1999.17.9.2971","volume":"17","author":"RJ Gralla","year":"1999","unstructured":"Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971\u201394. https:\/\/doi.org\/10.1200\/jco.1999.17.9.2971","journal-title":"J Clin Oncol"},{"issue":"11","key":"9638_CR7","first-page":"57","volume":"11","author":"NCCN","year":"1997","unstructured":"NCCN (1997) NCCN antiemesis practice guidelines. Oncology (Williston Park) 11(11):57\u201389","journal-title":"Oncology (Williston Park)"},{"issue":"8","key":"9638_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1023\/A:1008471812316","volume":"9","author":"F Roila","year":"1998","unstructured":"Roila F (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol 9(8):811\u20139","journal-title":"Ann Oncol"},{"issue":"24","key":"9638_CR9","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/jco.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38(24):2782\u20132797. https:\/\/doi.org\/10.1200\/jco.20.01296","journal-title":"J Clin Oncol"},{"key":"9638_CR10","unstructured":"NCCN (2025) NCCN Clinical practice guidelines in oncology (NCCN Guidelines Version 2.2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 11 Jun 1999"},{"issue":"1","key":"9638_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00520-023-08221-4","volume":"32","author":"J Herrstedt","year":"2023","unstructured":"Herrstedt J, Celio L, Hesketh PJ, Zhang L, Navari R, Chan A et al (2023) 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Support Care Cancer 32(1):47. https:\/\/doi.org\/10.1007\/s00520-023-08221-4","journal-title":"Support Care Cancer"},{"issue":"1","key":"9638_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00520-023-08222-3","volume":"32","author":"F Scott\u00e9","year":"2023","unstructured":"Scott\u00e9 F, Schwartzberg L, Iihara H, Aapro M, Gralla R, Hesketh PJ et al (2023) 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer 32(1):45. https:\/\/doi.org\/10.1007\/s00520-023-08222-3","journal-title":"Support Care Cancer"},{"issue":"8","key":"9638_CR13","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, Pel\u00e1ez I, Rodr\u00edguez-Lescure \u00c1, Pastorelli D et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986\u20131992. https:\/\/doi.org\/10.1093\/annonc\/mds021","journal-title":"Ann Oncol"},{"issue":"1","key":"9638_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/jop.2012.000816","volume":"10","author":"JW Gilmore","year":"2014","unstructured":"Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J et al (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 10(1):68\u201374. https:\/\/doi.org\/10.1200\/jop.2012.000816","journal-title":"J Oncol Pract"},{"issue":"2","key":"9638_CR15","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL et al (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9(2):102195. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","journal-title":"ESMO Open"},{"key":"9638_CR16","unstructured":"Education OM (2022) Survey on the HCPs perspectives on CINV in stem cell transplant. https:\/\/ologyeducation.org\/wp-content\/uploads\/2022\/11\/Outcomes-CINV-SurveyOlogy2022.11.15.pdf. Accessed 11 Jun 1999"},{"issue":"5","key":"9638_CR17","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00520-013-2072-4","volume":"22","author":"SP Yeh","year":"2014","unstructured":"Yeh SP, Lo WC, Hsieh CY, Bai LY, Lin CC, Lin PH et al (2014) Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. Support Care Cancer 22(5):1199\u20131206. https:\/\/doi.org\/10.1007\/s00520-013-2072-4","journal-title":"Support Care Cancer"},{"issue":"30","key":"9638_CR18","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1200\/jco.2013.55.0095","volume":"32","author":"T Schmitt","year":"2014","unstructured":"Schmitt T, Goldschmidt H, Neben K, Freiberger A, H\u00fcsing J, Gronkowski M et al (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32(30):3413\u20133420. https:\/\/doi.org\/10.1200\/jco.2013.55.0095","journal-title":"J Clin Oncol"},{"issue":"1","key":"9638_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000371523","volume":"89","author":"A Svanberg","year":"2015","unstructured":"Svanberg A, Birgeg\u00e5rd G (2015) Addition of aprepitant (Emend\u00ae) to standard antiemetic Regimen continued for 7 days after chemotherapy for stem cell transplantation provides significant reduction of vomiting. Oncology 89(1):31\u201336. https:\/\/doi.org\/10.1159\/000371523","journal-title":"Oncology"},{"issue":"1","key":"9638_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbmt.2012.07.019","volume":"19","author":"PJ Stiff","year":"2013","unstructured":"Stiff PJ, Fox-Geiman MP, Kiley K, Rychlik K, Parthasarathy M, Fletcher-Gonzalez D et al (2013) Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19(1):49-55.e1. https:\/\/doi.org\/10.1016\/j.bbmt.2012.07.019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"9638_CR21","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41409-018-0106-8","volume":"53","author":"J Bubalo","year":"2018","unstructured":"Bubalo J, Mulverhill K, Meyers G, Hayes-Lattin B, Maziarz R (2018) A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant 53(8):1010\u20131018. https:\/\/doi.org\/10.1038\/s41409-018-0106-8","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"9638_CR22","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.bbmt.2018.06.005","volume":"24","author":"AB Clemmons","year":"2018","unstructured":"Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24(10):2065\u20132071. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"9638_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00520-021-06472-7","volume":"30","author":"B Loteta","year":"2022","unstructured":"Loteta B, Paviglianiti A, Naso V, Ferreri A, Moscato T, Console G et al (2022) Netupitant\/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience. Support Care Cancer 30(1):585\u2013591. https:\/\/doi.org\/10.1007\/s00520-021-06472-7","journal-title":"Support Care Cancer"},{"issue":"9","key":"9638_CR24","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00277-020-04180-6","volume":"99","author":"V Apolito","year":"2020","unstructured":"Apolito V, Giaccone L, Ferrero S, Larocca A, Cavallo F, Coscia M et al (2020) Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Ann Hematol 99(9):2197\u20132199. https:\/\/doi.org\/10.1007\/s00277-020-04180-6","journal-title":"Ann Hematol"},{"issue":"11","key":"9638_CR25","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s00520-014-2248-6","volume":"22","author":"T Bechtel","year":"2014","unstructured":"Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr et al (2014) Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 22(11):2911\u20132916. https:\/\/doi.org\/10.1007\/s00520-014-2248-6","journal-title":"Support Care Cancer"},{"issue":"4","key":"9638_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12185-016-2152-6","volume":"105","author":"A Isoda","year":"2017","unstructured":"Isoda A, Saito R, Komatsu F, Negishi Y, Oosawa N, Ishikawa T et al (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol 105(4):478\u2013484. https:\/\/doi.org\/10.1007\/s12185-016-2152-6","journal-title":"Int J Hematol"},{"issue":"6","key":"9638_CR27","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/bmt.2010.205","volume":"46","author":"K Jordan","year":"2011","unstructured":"Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J et al (2011) The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 46(6):784\u2013789. https:\/\/doi.org\/10.1038\/bmt.2010.205","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"9638_CR28","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00520-021-06495-0","volume":"30","author":"N Di Renzo","year":"2022","unstructured":"Di Renzo N, Musso M, Scim\u00e8 R, Cupri A, Perrone T, De Risi C et al (2022) Efficacy and safety of netupitant\/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin\u2019s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation. Support Care Cancer 30(2):1521\u20131527. https:\/\/doi.org\/10.1007\/s00520-021-06495-0","journal-title":"Support Care Cancer"},{"issue":"11","key":"9638_CR29","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41409-020-0909-2","volume":"55","author":"N Di Renzo","year":"2020","unstructured":"Di Renzo N, Musso M, Scim\u00e8 R, Cupri A, Perrone T, De Risi C et al (2020) Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. Bone Marrow Transplant 55(11):2114\u20132120. https:\/\/doi.org\/10.1038\/s41409-020-0909-2","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"9638_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/10781552231173863","volume":"30","author":"JS Bubalo","year":"2024","unstructured":"Bubalo JS, Radke JL, Bensch KG, Chen AI, Misra S, Maziarz RT (2024) A phase II trial of netupitant\/palonosetron for prevention of chemotherapy-induced nausea\/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation. J Oncol Pharm Pract 30(2):304\u2013312. https:\/\/doi.org\/10.1177\/10781552231173863","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"9638_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1078155209105399","volume":"16","author":"B Paul","year":"2010","unstructured":"Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O (2010) Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 16(1):45\u201351. https:\/\/doi.org\/10.1177\/1078155209105399","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"9638_CR32","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1007\/s00520-011-1341-3","volume":"20","author":"MH Abidi","year":"2012","unstructured":"Abidi MH, Tageja N, Ayash L, Abrams J, Ratanatharathorn V, Al-Kadhimi Z et al (2012) Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial. Support Care Cancer 20(10):2363\u20132369. https:\/\/doi.org\/10.1007\/s00520-011-1341-3","journal-title":"Support Care Cancer"},{"issue":"1","key":"9638_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/bmt.2009.114","volume":"45","author":"M Musso","year":"2010","unstructured":"Musso M, Scalone R, Crescimanno A, Bonanno V, Polizzi V, Porretto F et al (2010) Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 45(1):123\u2013127. https:\/\/doi.org\/10.1038\/bmt.2009.114","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"9638_CR34","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1177\/1078155218790345","volume":"25","author":"J LaPorte","year":"2019","unstructured":"LaPorte J, Leone K, Zhang X, Holland K, Morris L, Bashey A et al (2019) A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy. J Oncol Pharm Pract 25(6):1336\u20131342. https:\/\/doi.org\/10.1177\/1078155218790345","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"9638_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/annonc\/mdq457","volume":"22","author":"SA Giralt","year":"2011","unstructured":"Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD et al (2011) Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 22(4):939\u2013946. https:\/\/doi.org\/10.1093\/annonc\/mdq457","journal-title":"Ann Oncol"},{"issue":"1","key":"9638_CR36","first-page":"84","volume":"91","author":"J L\u00f3pez-Jim\u00e9nez","year":"2006","unstructured":"L\u00f3pez-Jim\u00e9nez J, Mart\u00edn-Ballesteros E, Sureda A, Uralburu C, Lorenzo I, del Campo R et al (2006) Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 91(1):84\u201391","journal-title":"Haematologica"},{"issue":"6","key":"9638_CR37","doi-asserted-by":"publisher","first-page":"102911","DOI":"10.1016\/j.transci.2020.102911","volume":"59","author":"M Martino","year":"2020","unstructured":"Martino M, Naso V, Porto G, Paviglianiti A, Ferreri A, Loteta B et al (2020) Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: an observational real-world study of effectiveness and safety. Transfus Apher Sci 59(6):102911. https:\/\/doi.org\/10.1016\/j.transci.2020.102911","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"9638_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/bf02982608","volume":"77","author":"S Matsuoka","year":"2003","unstructured":"Matsuoka S, Okamoto S, Watanabe R, Mori T, Nagayama H, Hamano Y et al (2003) Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Int J Hematol 77(1):86\u201390. https:\/\/doi.org\/10.1007\/bf02982608","journal-title":"Int J Hematol"},{"issue":"23","key":"9638_CR39","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.2217\/fon-2021-0023","volume":"17","author":"RM Navari","year":"2021","unstructured":"Navari RM, Binder G, Bonizzoni E, Clark-Snow R, Olivari S, Roeland EJ (2021) Single-dose netupitant\/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol 17(23):3027\u20133035. https:\/\/doi.org\/10.2217\/fon-2021-0023","journal-title":"Future Oncol"},{"issue":"2","key":"9638_CR40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/jco.21.01315","volume":"40","author":"A Hata","year":"2022","unstructured":"Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K et al (2022) Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol 40(2):180\u2013188. https:\/\/doi.org\/10.1200\/jco.21.01315","journal-title":"J Clin Oncol"},{"issue":"1","key":"9638_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40487-022-00188-2","volume":"10","author":"A Hata","year":"2022","unstructured":"Hata A, Shiraishi Y, Inui N, Okada M, Morise M, Akiyoshi K et al (2022) Exploratory analysis comparing fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, phase 3 study (CONSOLE). Oncol Ther 10(1):253\u2013262. https:\/\/doi.org\/10.1007\/s40487-022-00188-2","journal-title":"Oncol Ther"},{"key":"9638_CR42","doi-asserted-by":"publisher","first-page":"S1640","DOI":"10.1016\/j.annonc.2023.10.541","volume":"34","author":"F Scott\u00e9","year":"2023","unstructured":"Scott\u00e9 F, Zelek L, Guiliano C, Olivari TS, Bailey WL, Ruhlmann CH, Iihara H, Aapro M (2023) Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period. Ann Oncol 34:S1640. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.541","journal-title":"Ann Oncol"},{"key":"9638_CR43","unstructured":"Denson A, Wiggins A, Martin A, Arnall J. (2020) Nausea and vomiting in adult patients undergoing hematopoietic stem-cell transplant: is olanzapine an option? JHOP. 10(2)."},{"issue":"3","key":"9638_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s44228-022-00012-8","volume":"4","author":"S Yuda","year":"2022","unstructured":"Yuda S, Fuji S, Savani B, Gatwood KS (2022) Antiemetic strategies in patients who undergo hematopoietic stem cell transplantation. Clin Hematol Int 4(3):89\u201398. https:\/\/doi.org\/10.1007\/s44228-022-00012-8","journal-title":"Clin Hematol Int"},{"issue":"3","key":"9638_CR45","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00520-018-4594-2","volume":"27","author":"A Tendas","year":"2019","unstructured":"Tendas A, Marchesi F, Mengarelli A, Annibali O, Tomarchio V, Saltarelli D et al (2019) Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Support Care Cancer 27(3):793\u2013803. https:\/\/doi.org\/10.1007\/s00520-018-4594-2","journal-title":"Support Care Cancer"},{"issue":"5","key":"9638_CR46","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/ejh.14282","volume":"113","author":"N B\u00e1ez-Guti\u00e9rrez","year":"2024","unstructured":"B\u00e1ez-Guti\u00e9rrez N, Su\u00e1rez-Casillas P, P\u00e9rez-Moreno MA, Bl\u00e1zquez-Go\u00f1i C, Abdelkader-Mart\u00edn L (2024) Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review. Eur J Haematol 113(5):564\u201375. https:\/\/doi.org\/10.1111\/ejh.14282","journal-title":"Eur J Haematol"},{"issue":"2","key":"9638_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.46765\/2675-374X.2023v4n2p187","volume":"4","author":"L Arcuri","year":"2023","unstructured":"Arcuri L (2023) Antiemetics in hematopoietic cell transplantation: an overview of randomized trials. J Bone Marrow Transplan Cell Ther 4(2):187. https:\/\/doi.org\/10.46765\/2675-374X.2023v4n2p187","journal-title":"J Bone Marrow Transplan Cell Ther"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09638-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09638-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09638-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:06:37Z","timestamp":1757196397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09638-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["9638"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09638-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KJ reports personal fees as an invited speaker from Amgen, art tempi, Helsinn, Hexal, BMS, Merck, med update GmbH, Peer Voice, Mundipharma, Esteve, Roche, Shire (Takeda), Astra Zeneca and Astellas; personal fees for advisory board membership from Dompe, Stemline, AstraZeneca, BD Solutions, Hexal, Karyopharma, Voluntis, Abbot, Pfizer and Helsinn; royalties from Elsevier and UpToDate. BJ reports personal fees as an invited speaker from Alexion Pharmaceuticals, Argenx, Temmler, and UCB, and personal fees for advisory board membership from Alexion Pharmaceuticals and UCB. JV reports receiving consultancy fees from Helsinn Healthcare. FJ reports reports personal fees as an invited speaker from Amgen, Esteve and Astellas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"622"}}